295 related articles for article (PubMed ID: 30926356)
21. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
22. The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis.
Qin Q; Peng B; Li B
Expert Rev Anticancer Ther; 2019 Jun; 19(6):533-539. PubMed ID: 31104529
[No Abstract] [Full Text] [Related]
23. Molecular Testing for EGFR Mutations and ALK Rearrangements in the Cytological Specimens From the Patients With Non-Small Cell Lung Cancer.
Wang X; Chen S; Emerson RE; Wu HH; Cramer HM; Curless K; Chang HY; Zhang S; Randolph ML; Cheng L
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):119-124. PubMed ID: 30688675
[TBL] [Abstract][Full Text] [Related]
24. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
25. Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses.
Ni J; Li G; Yang X; Chu L; Wang J; Li Y; Zou L; Li Y; Xie C; Zhu Z
Radiat Oncol; 2019 Mar; 14(1):44. PubMed ID: 30866974
[TBL] [Abstract][Full Text] [Related]
26. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
27. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
[TBL] [Abstract][Full Text] [Related]
28. Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma.
Nakashima T; Nonoshita T; Hirata H; Inoue K; Nagashima A; Yoshitake T; Asai K; Shioyama Y
In Vivo; 2020; 34(1):247-253. PubMed ID: 31882485
[TBL] [Abstract][Full Text] [Related]
29. Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer.
Komurcuoglu B; Karakurt G; Kaya OO; Diniz G; Kırbıyık O; Evkan A; Yalnız E
J Cancer Res Ther; 2023 Apr; 19(Supplement):S183-S190. PubMed ID: 37147996
[TBL] [Abstract][Full Text] [Related]
30. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
31. Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis.
Wang Z; Yang H; Luo S; Liu B; Zhang N; Li L; Zhou S; Shen R; Xie X
Lung Cancer; 2017 Oct; 112():1-9. PubMed ID: 29191580
[TBL] [Abstract][Full Text] [Related]
32. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
33. [Driven Gene in Patients with Lung Squamous Cell Carcinoma:
Analysis of Clinicopathologic Characteristics and Prognosis].
Zhang T; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
[TBL] [Abstract][Full Text] [Related]
34. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
Sauter JL; Butnor KJ
Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
36. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
37. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
38. EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer.
Satoh Y; Matsuo Y; Kuba T; Yamashita K; Sawano M; Tozaka S; Yamazaki H; Sonoda D; Mikubo M; Naito M; Matsui Y; Shiomi K; Yoshida T; Murakumo Y
Virchows Arch; 2020 May; 476(5):753-762. PubMed ID: 31823000
[TBL] [Abstract][Full Text] [Related]
39. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G
Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898
[TBL] [Abstract][Full Text] [Related]
40. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]